Literature DB >> 18180761

Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder.

S Saxena1, E Gorbis, J O'Neill, S K Baker, M A Mandelkern, K M Maidment, S Chang, N Salamon, A L Brody, J M Schwartz, E D London.   

Abstract

Brief intensive cognitive-behavioral therapy (CBT) using exposure and response prevention significantly improves obsessive-compulsive disorder (OCD) symptoms in as little as 4 weeks. However, it has been thought that much longer treatment was needed to produce the changes in brain function seen in neuroimaging studies of OCD. We sought to elucidate the brain mediation of response to brief intensive CBT for OCD and determine whether this treatment could induce functional brain changes previously seen after longer trials of pharmacotherapy or standard CBT. [(18)F]-fluorodeoxyglucose positron emission tomography brain scans were obtained on 10 OCD patients before and after 4 weeks of intensive individual CBT. Twelve normal controls were scanned twice, several weeks apart, without treatment. Regional glucose metabolic changes were compared between groups. OCD symptoms, depression, anxiety and overall functioning improved robustly with treatment. Significant changes in normalized regional glucose metabolism were seen after brief intensive CBT (P=0.04). Compared to controls, OCD patients showed significant bilateral decreases in normalized thalamic metabolism with intensive CBT but had a significant increase in right dorsal anterior cingulate cortex activity that correlated strongly with the degree of improvement in OCD symptoms (P=0.02). The rapid response of OCD to intensive CBT is mediated by a distinct pattern of changes in regional brain function. Reduction of thalamic activity may be a final common pathway for improvement in OCD, but response to intensive CBT may require activation of dorsal anterior cingulate cortex, a region involved in reappraisal and suppression of negative emotions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180761      PMCID: PMC2893580          DOI: 10.1038/sj.mp.4002134

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  62 in total

1.  Structural and functional dichotomy of human midcingulate cortex.

Authors:  Brent A Vogt; Gail R Berger; Stuart W G Derbyshire
Journal:  Eur J Neurosci       Date:  2003-12       Impact factor: 3.386

2.  Neocortical modulation of the amygdala response to fearful stimuli.

Authors:  Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Francesco Fera; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2003-03-15       Impact factor: 13.382

Review 3.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

Authors:  G E Alexander; M R DeLong; P L Strick
Journal:  Annu Rev Neurosci       Date:  1986       Impact factor: 12.449

4.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

5.  Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder.

Authors:  D-H Kang; J S Kwon; J-J Kim; T Youn; H-J Park; M S Kim; D S Lee; M C Lee
Journal:  Acta Psychiatr Scand       Date:  2003-04       Impact factor: 6.392

6.  Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder.

Authors:  Jun Soo Kwon; Jae-Jin Kim; Dong Woo Lee; Jae Sung Lee; Dong Soo Lee; Myung-Sun Kim; In Kyoon Lyoo; Maeng Je Cho; Myung Chul Lee
Journal:  Psychiatry Res       Date:  2003-01-20       Impact factor: 3.222

7.  Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder.

Authors:  Eriko Nakatani; Akiko Nakgawa; Yoko Ohara; Shoko Goto; Naruhiko Uozumi; Michiyo Iwakiri; Yukari Yamamoto; Keisuke Motomura; Yasuro Iikura; Toshiko Yamagami
Journal:  Psychiatry Res       Date:  2003-10-30       Impact factor: 3.222

8.  Pharmacotherapy and regional cerebral blood flow in children with obsessive compulsive disorder.

Authors:  Rasim Somer Diler; Mustafa Kibar; Ayse Avci
Journal:  Yonsei Med J       Date:  2004-02-29       Impact factor: 2.759

9.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.

Authors:  L R Baxter; M E Phelps; J C Mazziotta; B H Guze; J M Schwartz; C E Selin
Journal:  Arch Gen Psychiatry       Date:  1987-03

10.  Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.

Authors:  Kimberly Goldapple; Zindel Segal; Carol Garson; Mark Lau; Peter Bieling; Sidney Kennedy; Helen Mayberg
Journal:  Arch Gen Psychiatry       Date:  2004-01
View more
  38 in total

1.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

2.  Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.

Authors:  Frederike Schirmbeck; Daniela Mier; Christine Esslinger; Franziska Rausch; Susanne Englisch; Sarah Eifler; Andreas Meyer-Lindenberg; Peter Kirsch; Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

Review 3.  Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective.

Authors:  David L Pauls; Amitai Abramovitch; Scott L Rauch; Daniel A Geller
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

4.  MRSI correlates of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  Joseph O'Neill; John C Piacentini; Susanna Chang; Jennifer G Levitt; Michelle Rozenman; Lindsey Bergman; Noriko Salamon; Jeffry R Alger; James T McCracken
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-10-01       Impact factor: 5.067

Review 5.  Towards medication-enhancement of cognitive interventions in schizophrenia.

Authors:  Hsun-Hua Chou; Elizabeth Twamley; Neal R Swerdlow
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial.

Authors:  Marcelo Queiroz Hoexter; Fábio Luis de Souza Duran; Carina Chaubet D'Alcante; Darin Dean Dougherty; Roseli Gedanke Shavitt; Antonio Carlos Lopes; Juliana Belo Diniz; Thilo Deckersbach; Marcelo Camargo Batistuzzo; Rodrigo Affonseca Bressan; Euripedes Constantino Miguel; Geraldo Filho Busatto
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

7.  Are we studying and treating schizophrenia correctly?

Authors:  Neal R Swerdlow
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

Review 8.  Neuroimaging for psychotherapy research: current trends.

Authors:  Carol P Weingarten; Timothy J Strauman
Journal:  Psychother Res       Date:  2014-02-17

9.  Cognitive behavioral management of Tourette's syndrome and chronic tic disorder in medicated and unmedicated samples.

Authors:  Kieron P O'Connor; Anick Laverdure; Annie Taillon; Emmanuel Stip; François Borgeat; Marc Lavoie
Journal:  Behav Res Ther       Date:  2009-08-05

10.  Error-related negativity and tic history in pediatric obsessive-compulsive disorder.

Authors:  Gregory L Hanna; Melisa Carrasco; Shannon M Harbin; Jenna K Nienhuis; Christina E LaRosa; Poyu Chen; Kate D Fitzgerald; William J Gehring
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-07-25       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.